United Therapeutics (BSP:U2TH34) Cyclically Adjusted Book per Share: R$26.52 (As of Mar. 2026)


BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
65 GF Score
Price R$137.50
GF Value R$97.21
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Cyclically Adjusted Book per Share?

United Therapeutics BSP:U2TH34 65 Cyclically Adjusted Book per Share is R$26.52 as of Mar. 2026. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$97.21 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

United Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was R$36.602. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$26.52 for the trailing ten years ended in Mar. 2026.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Book Growth Rate was 15.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 16.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 19.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of United Therapeutics was 22.10% per year. The lowest was 16.90% per year. And the median was 18.70% per year.

As of today (2026-07-08), United Therapeutics's current stock price is R$137.50. United Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was R$26.52. United Therapeutics's Cyclically Adjusted PB Ratio of today is 5.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of United Therapeutics was 8.18. The lowest was 2.27. And the median was 4.02.


United Therapeutics  (BSP:U2TH34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=137.50/26.52
=5.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of United Therapeutics was 8.18. The lowest was 2.27. And the median was 4.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


United Therapeutics Cyclically Adjusted Book per Share Related Terms


United Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Cyclically Adjusted Book per Share Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 18.93 26.78 27.44

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.36 25.59 25.83 27.44 26.52

BSP:U2TH34 vs VTRS, NBIX, ZTS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PB Ratio falls into.


BSP:U2TH34
65GF Score
United Therapeutics Corp BSP:U2TH34
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=36.602/330.2130*330.2130
=36.602

Current CPI (Mar. 2026) = 330.2130.

United Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 7.069 241.018 9.685
201609 7.011 241.428 9.589
201612 7.226 241.432 9.883
201703 7.169 243.801 9.710
201706 6.737 244.955 9.082
201709 7.503 246.819 10.038
201712 8.008 246.524 10.727
201803 8.943 249.554 11.833
201806 11.105 251.989 14.552
201809 12.692 252.439 16.602
201812 12.422 251.233 16.327
201903 10.166 254.202 13.206
201906 11.248 256.143 14.501
201909 12.748 256.759 16.395
201912 13.002 256.974 16.708
202003 16.371 258.115 20.944
202006 18.093 257.797 23.175
202009 19.947 260.280 25.306
202012 19.623 260.474 24.877
202103 21.674 264.877 27.020
202106 20.384 271.696 24.774
202109 22.453 274.310 27.029
202112 24.815 278.802 29.391
202203 22.946 287.504 26.355
202206 23.959 296.311 26.700
202209 26.252 296.808 29.207
202212 27.329 296.797 30.406
202303 28.571 301.836 31.257
202306 27.991 305.109 30.294
202309 30.023 307.789 32.210
202312 31.169 306.746 33.554
202403 30.068 312.332 31.789
202406 34.539 314.175 36.302
202409 37.863 315.301 39.654
202412 43.848 315.605 45.878
202503 43.480 319.799 44.896
202506 43.993 322.561 45.037
202509 41.190 324.800 41.876
202512 44.354 324.054 45.197
202603 36.602 330.213 36.602

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of R$26.52 mean?
United Therapeutics (BSP:U2TH34) has a Cyclically Adjusted Book per Share of R$26.52 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Cyclically Adjusted Book per Share too high?
United Therapeutics' current Cyclically Adjusted Book per Share is R$26.52. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Cyclically Adjusted Book per Share compare to VTRS and NBIX?
United Therapeutics' Cyclically Adjusted Book per Share of R$26.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on United Therapeutics and its competitors. United Therapeutics's current Cyclically Adjusted Book per Share is R$26.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$97.21, compared to a current price of R$137.50 — trading 41.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is R$26.52. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Cyclically Adjusted Book per Share is R$26.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$137.50 is trading 41.4% above its estimated GF Value™ of R$97.21. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for BSP:U2TH34:

  • Cyclically Adjusted Book per Share: R$26.52
  • GF Value™: R$97.21 vs. price of R$137.50 (41.4% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score

Get the complete analysis for BSP:U2TH34

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$137.50
Price
R$97.21
GF Value